Stockreport

SNGX: Positive Results for Phase 2a Trial in Psoriasis [Yahoo! Finance]

Soligenix, Inc.  (SNGX) 
NASDAQ:AMEX Investor Relations: soligenix.com/investors
PDF On December 17, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced positive results from Cohort 3 of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treat [Read more]